Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Targeted Inhibition of Myeloperoxidase (MPO): A New Therapeutic Strategy for the Treatment of Multiple Myeloma

Connor Williams, Jacqueline Noll, Dylan Harnas, Hayley Parkinson, Duncan Hewett, Kaitlin Wyllie, Thomas Cox, Andrew Zannettino, Kate Vandyke, Vasilios Panagopoulos

Blood (2023) 142 (Supplement 1): 3319.

https://doi.org/10.1182/blood-2023-179196

Published: 2023

Journal Articles

A Functional Genomic Screen to Identify Novel Genes Involved in Multiple Myeloma Tumour Development

Hayley Parkinson, James Breen, Nhi Hin, Vasilios Panagopoulos, Andrew Zannettino, Kate Vandyke, Duncan Hewett

Blood (2023) 142 (Supplement 1): 1947.

https://doi.org/10.1182/blood-2023-174601

Published: 2023

Journal Articles

Hypoxia Inducible Factor (HIF)-2α Enhances Proliferation Of Malignant Hematopoietic Cells In The Hypoxic Malignant Bone Marrow

Catherine E Forristal, PhD, Falak Helwani, PhD, Sally Martin, Bianca Nowlan, Ingrid G Winkler, PhD, Andrew Zannettino, Jean-Pierre Levesque, PhD

Blood (2013) 122 (21): 2895.

https://doi.org/10.1182/blood.V122.21.2895.2895

Published: 2013

Journal Articles

Ethylene Diamine Tetra Acetic Acid (EDTA) Decalcification of Paediatric Bone Marrow Trephines In a Diagnostic Laboratory

Shriram Vaidia Nath, FRCPA, DM, MD, D.Ped, MBBS, Michelle Tamblyn, Dip., Med., Tech, Grad, Cert, Surg, Path, Prep, Susan Telfer, BSc(Hons), Grad, Cert, Surg, Path, Prep, Tony Henwood, JP, MSc, BAppSc, GradDipSysAnalys, CT(ASC), Peter Gilham, Colin Story, MSc, Greg Hodge, PhD, Akash Kalro, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Ram Suppiah, MBBS, FRACP, FRCPA, Heather Tapp, MBBS, FRACP, FRCPA, Ian C Nicholson, PhD, BSc(Hons), BSc, Heddy Zola, PhD, FRCPA, Sarah Moore, B, App, Sci, BSc(Hons), Andrew Zannettino, BSc, PhD, Nick Manton, FRCPA, Tamas Revesz, MD, PhD, FRACP

Blood (2010) 116 (21): 2566.

https://doi.org/10.1182/blood.V116.21.2566.2566

Published: 2010

Journal Articles

The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34 + cells

Jane R. Engler, Amity Frede, Verity Saunders, Andrew Zannettino, Deborah L. White, Timothy P. Hughes

Blood (2010) 116 (15): 2776–2778.

https://doi.org/10.1182/blood-2010-01-267013

Published: 2010

Journal Articles

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

Deborah L. White, Verity A. Saunders, Phuong Dang, Jane Engler, Amity Venables, Stephanie Zrim, Andrew Zannettino, Kevin Lynch, Paul W. Manley, Timothy Hughes

Blood (2007) 110 (12): 4064–4072.

https://doi.org/10.1182/blood-2007-06-093617

Published: 2007

Includes: Supplemental data

Journal Articles

Molecular Response to Imatinib Is Dependent on Dose in CML Patients with Low OCT-1 Influx Activity. Patients with High Activity May Respond Equally Well to Standard or Increased Dose Imatinib.

Deborah White, Verity Saunders, Phuong Dang, Amity Venables, Steph Zrim, John Reynolds, Steven Quinn, Andrew Zannettino, Timothy Hughes

Blood (2006) 108 (11): 738.

https://doi.org/10.1182/blood.V108.11.738.738

Published: 2006

Journal Articles

ABCB1 Overexpression May Predispose Imatinib Treated CML Patients to the Development of Abl Kinase Domain Mutations, and May Be an Important Contributor to Acquired Resistance.

Deborah White, Phuong Dang, Amity Venables, Verity Saunders, Stephanie Zrim, Andrew Zannettino, Peter Diamond, Steven Quinn, Luen Bik To, Timothy Hughes

Blood (2006) 108 (11): 2144.

https://doi.org/10.1182/blood.V108.11.2144.2144

Published: 2006

Journal Articles

Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells

Angela Kortesidis, Andrew Zannettino, Sandra Isenmann, Songtao Shi, Tsvee Lapidot, Stan Gronthos

Blood (2005) 105 (10): 3793–3801.

https://doi.org/10.1182/blood-2004-11-4349

Published: 2005

NARROW

Targeted Inhibition of Myeloperoxidase (MPO): A New Therapeutic Strategy for the Treatment of Multiple Myeloma

A Functional Genomic Screen to Identify Novel Genes Involved in Multiple Myeloma Tumour Development

Hypoxia Inducible Factor (HIF)-2α Enhances Proliferation Of Malignant Hematopoietic Cells In The Hypoxic Malignant Bone Marrow

Ethylene Diamine Tetra Acetic Acid (EDTA) Decalcification of Paediatric Bone Marrow Trephines In a Diagnostic Laboratory

The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34 + cells

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

Molecular Response to Imatinib Is Dependent on Dose in CML Patients with Low OCT-1 Influx Activity. Patients with High Activity May Respond Equally Well to Standard or Increased Dose Imatinib.

ABCB1 Overexpression May Predispose Imatinib Treated CML Patients to the Development of Abl Kinase Domain Mutations, and May Be an Important Contributor to Acquired Resistance.

Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only